SecBot SecBot

MIST

Milestone Pharmaceuticals Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A8· CIK 0001408443 Biotech & Drug Discovery
$0.6444 −0.00 (−0.56%)
Oct 26 4:00 PM ET · prev $0.6480
Market cap
$87.5M
Micro cap
Consensus
Buy
85% Buy or better · 13 analysts
Median target
$7.00
+986% · range $1.00–8.00
Next earnings
Nov 17
in 22 days · EPS est. −$0.21
1 year
−66.3%
from $1.91 · Oct 27
30 days
−18.9%
from $0.7950
52-week range
$0.6444–2.95
at the low
Avg volume 20D
983.1K
shares / day
Short interest
19.01M
≈15.3% of shares · +3.5%
Days to cover
16.0
at average volume
Insider net
−$82.5K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 3 reports · 90 days
Balance 1 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 17, 2026
Strongest BULLISH China's NMPA approved Milestone's etripamil nasal spray (CARDAMYST) for PSVT in adults, marking the first…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $82.5K.

  • InstitutionsBEARISH

    Q2 2026: 5 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    11 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.210 → −$0.214 over 90 days. 2 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.5% to 19.01M shares. 16.0 days to cover, ≈15.3% of shares.

  • TrendDOWNTREND

    30% below its 50-day average. New closing low $0.6444 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Point72 Asset Management, L.P.DOUBLED5,411,138$7.3M
MILLENNIUM MANAGEMENT LLCDOUBLED3,142,219$4.2M
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM359,895$482.3K
Squarepoint Ops LLCTRIM231,824$310.6K
BALYASNY ASSET MANAGEMENT L.P.TRIM220,498$295.5K
Wealthspire Advisors, LLCDOUBLED140,629$188.4K
Quadrature Capital LtdTRIM64,661$86.6K
JANE STREET GROUP, LLCTRIM57,787$77.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 85% rate it Buy or better
Strong Buy3Buy8Hold2Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +986%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 3, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 20, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
May 14, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$82.5K
sold · 1 insider
DateInsiderTypeValue
Jun 10, 2026
Giles Lisa M.
Director
AWARD77,000 sh
Jun 10, 2026
Fischer Seth H. Z.
Director
AWARD77,000 sh
Jun 10, 2026
Duty Stuart
Director
AWARD77,000 sh
Jun 10, 2026
Wills Robert James
Director
AWARD77,000 sh
Jun 10, 2026
TOMSICEK MICHAEL JOHN
Director
AWARD77,000 sh
Jun 10, 2026
Saik Andrew
Director
AWARD77,000 sh
Apr 16, 2026
Oliveto Joseph
President and CEO
SELL$82.5K
Feb 2, 2026
Bharucha David
Chief Medical Officer
AWARD204,000 sh

Earnings setup

Estimates
Nov 17
reports in 22 days
−$0.21
EPS estimate, this quarter
−2%
estimate change, 90 days
2↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.23–-$0.20-0.9%$1.0M
Next Q-$0.23-$0.27–-$0.20-0.9%$1.8M
Current FY-$0.84-$0.90–-$0.77-0.5%$3.5M
Next FY-$0.78-$0.96–-$0.59-1.3%$19.6M

Short side

FINRA· Sep 30, 2026
19,009,468
shares short
+3.5%
vs prior settlement
16.0
days to cover
≈15.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Other
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nas
Sep 3, 2026 SEC
China's NMPA approved Milestone's etripamil nasal spray (CARDAMYST) for PSVT in adults, marking the first regulatory…
8-K — Impact 6/10
Aug 21, 2026 Press
Milestone Pharmaceuticals announced first patient enrollment in the Phase 3 ReVeRA-301 pivotal trial evaluating…
Impact 7/10
Aug 12, 2026 SEC
Milestone Pharmaceuticals reported Q2 2026 results with product revenue of $0.6M, up from zero a year ago, but net…
8-K — Impact 6/10
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — DOUBLED
5,411,138 shares ($7.3M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
3,142,219 shares ($4.2M)
Jun 10, 2026 Insider
Giles Lisa M. was granted 77,000 shares
Director
Jun 10, 2026 Insider
Fischer Seth H. Z. was granted 77,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
MIST Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Oct 19, 2026
Press release
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused…
Aug 21, 2026
FDA
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
Aug 12, 2026
Earnings
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil)…
Aug 12, 2026
Earnings date
MIST Q2 2026 Earnings Scheduled — 2026-08-12
Jul 2, 2026
Press release
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today…

SecBot reports

6 filings · 3 press releases · 1 bullish · 3 bearish · 2 neutral
All MIST filing & press-release reports (9)